Floatz Rating
C39/100
Confidence
Indicative
Sponsor
IDEAYA Biosciences
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07277413CT.gov A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastric Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| MAT2A-IN-9 (this asset) | IDEAYA Biosciences | P1 | C · 39 |
| Fluorouracilum | Boehringer Ingelheim | P3 | BB |
| Capecitabine | Shanghai Zhongshan Hospital | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Mayo Clinic | P3 | BB |
| Trastuzumab | Boehringer Ingelheim | P2 | BB |
| Oxaliplatin | Shanghai Zhongshan Hospital | P3 | BB |
| Pembrolizumab | Epkin | P3 | BB |
| Durvalumab | University of California, Irvine | P2 | B |
| Irinotecan | Georgetown University | P3 | B |
+42 more in the Gastric Adenocarcinoma cohort
Other indications for MAT2A-IN-9
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P1/2 | B · 57 |
| Gastroesophageal Cancer | — | P1 | CC · 43 |
| Lung Adenocarcinoma | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. MAT2A-IN-9 in Gastric Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/mat2a-in-9-gastric-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →